| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6417191 | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Mar, 2016
(8 years ago) | |
| US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US6417191 (Pediatric) | VIIV HLTHCARE | Synergistic combinations of zidovudine, 1592U89 and 3TC |
Sep, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6294540 | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
May, 2018
(5 years ago) | |
|
US6294540 (Pediatric) | VIIV HLTHCARE | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Nov, 2018
(5 years ago) | |
Trizivir is owned by Viiv Hlthcare.
Trizivir contains Abacavir Sulfate; Lamivudine; Zidovudine.
Trizivir has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Trizivir are:
- US6417191
- US5905082
- US6417191*PED
- US5905082*PED
- US6294540
- US6294540*PED
Trizivir was authorised for market use on 14 November, 2000.
Trizivir is available in tablet;oral dosage forms.
Trizivir can be used as method of treatment of a patient infected with hiv, treatment of hiv.
The generics of Trizivir are possible to be released after 14 November, 2018.
Drugs and Companies using ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE ingredient
Market Authorisation Date: 14 November, 2000
Treatment: Treatment of hiv; Method of treatment of a patient infected with hiv
Dosage: TABLET;ORAL
TRIZIVIR family patents
